MA27440A1 - Derives de pyrazole servant d'inhibiteurs du facteur de croissance transformant(tgf) - Google Patents
Derives de pyrazole servant d'inhibiteurs du facteur de croissance transformant(tgf)Info
- Publication number
- MA27440A1 MA27440A1 MA28154A MA28154A MA27440A1 MA 27440 A1 MA27440 A1 MA 27440A1 MA 28154 A MA28154 A MA 28154A MA 28154 A MA28154 A MA 28154A MA 27440 A1 MA27440 A1 MA 27440A1
- Authority
- MA
- Morocco
- Prior art keywords
- tgf
- growth factor
- transforming growth
- inhibitors
- pyrazole derivatives
- Prior art date
Links
- 102000009618 Transforming Growth Factors Human genes 0.000 title abstract 7
- 108010009583 Transforming Growth Factors Proteins 0.000 title abstract 7
- 239000003112 inhibitor Substances 0.000 title abstract 3
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical class C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000003176 fibrotic effect Effects 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 150000003217 pyrazoles Chemical class 0.000 abstract 1
- 230000019491 signal transduction Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
REVENDICATION DE PRIORITES US 18 Septembre 2002 60/412,146 US 2 Juillet 2003 60/484,543 Voir en annexe le titre de l'invention et le texte de l'abrégé Dérivés de pyrazole servant d'inhibiteurs du facteur de croissance transformant (TGF) Des dérivés de pyrazole nouveaux de formule (Ia), des intermédiaires pour leur préparation, des compositions pharmaceutiques les contenant et leur utilisation en médecine sont décrits. Les composés de la présente invention sont de puissants inhibiteurs de la voie de transmission de signal du facteur de croissance transformant ("TGF")-(bêta). Ils sont utiles dans le traitement de divers états pathologiques en rapport avec le TGF, comprenant, par exemple, le cancer et des maladies fibrotiques.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41214602P | 2002-09-18 | 2002-09-18 | |
| US48454303P | 2003-07-02 | 2003-07-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA27440A1 true MA27440A1 (fr) | 2005-07-01 |
Family
ID=32033585
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA28154A MA27440A1 (fr) | 2002-09-18 | 2005-03-18 | Derives de pyrazole servant d'inhibiteurs du facteur de croissance transformant(tgf) |
Country Status (27)
| Country | Link |
|---|---|
| US (4) | US6958354B2 (fr) |
| EP (2) | EP1542684B1 (fr) |
| JP (1) | JP4519657B2 (fr) |
| KR (1) | KR20050044807A (fr) |
| CN (1) | CN1681501A (fr) |
| AP (1) | AP2005003263A0 (fr) |
| AR (1) | AR041272A1 (fr) |
| AT (1) | ATE450258T1 (fr) |
| AU (1) | AU2003259475A1 (fr) |
| BR (1) | BR0314302A (fr) |
| CA (1) | CA2496295C (fr) |
| CO (1) | CO5550456A2 (fr) |
| DE (1) | DE60330362D1 (fr) |
| EA (1) | EA200500377A1 (fr) |
| EC (1) | ECSP055679A (fr) |
| ES (1) | ES2335099T3 (fr) |
| HR (1) | HRP20050247A2 (fr) |
| IS (1) | IS7698A (fr) |
| MA (1) | MA27440A1 (fr) |
| MX (1) | MXPA05002376A (fr) |
| NO (1) | NO20050838L (fr) |
| OA (1) | OA12929A (fr) |
| PA (1) | PA8583201A1 (fr) |
| PE (1) | PE20040988A1 (fr) |
| PL (1) | PL375979A1 (fr) |
| UY (1) | UY27985A1 (fr) |
| WO (1) | WO2004026306A2 (fr) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60328028D1 (de) | 2002-09-18 | 2009-07-30 | Pfizer Prod Inc | Imidazolverbindungen als inhibitoren des transformierenden wachstumsfaktors (twf) |
| HRP20050250A2 (en) | 2002-09-18 | 2005-10-31 | Pfizer Products Inc. | Novel triazole and oxazole compounds as transforming growth factor (tfg) inhibitor |
| KR20050044807A (ko) * | 2002-09-18 | 2005-05-12 | 화이자 프로덕츠 인코포레이티드 | 전환 성장 인자 억제제로서의 피라졸 유도체 |
| CL2004000234A1 (es) * | 2003-02-12 | 2005-04-15 | Biogen Idec Inc | Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid |
| PA8595001A1 (es) | 2003-03-04 | 2004-09-28 | Pfizer Prod Inc | Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf) |
| GB0313915D0 (en) * | 2003-06-16 | 2003-07-23 | Smithkline Beecham Corp | Compounds |
| JP2008511630A (ja) * | 2004-08-31 | 2008-04-17 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | ＴＧＦ−βインヒビターとしてのピリミジニルピラゾール |
| EP1798229A4 (fr) * | 2004-09-07 | 2009-07-29 | Sankyo Co | Derive de biphenyle substitue |
| EP1804801A2 (fr) * | 2004-10-15 | 2007-07-11 | Biogen Idec MA, Inc. | Procede pour traiter des lesions vasculaires |
| TW200639163A (en) * | 2005-02-04 | 2006-11-16 | Genentech Inc | RAF inhibitor compounds and methods |
| KR20080082618A (ko) * | 2005-12-16 | 2008-09-11 | 알콘, 인코퍼레이티드 | Ａｌｋ5 조절제를 사용한 안압의 조절 |
| DK2089367T3 (da) | 2006-10-31 | 2012-02-06 | Pfizer Prod Inc | Pyrazolinforbindelser som mineralocorticoidreceptor-antagonister |
| KR20100038119A (ko) * | 2007-08-01 | 2010-04-12 | 화이자 인코포레이티드 | 피라졸 화합물 및 ｒａｆ 억제제로서 이의 용도 |
| JP6474166B2 (ja) | 2014-01-01 | 2019-02-27 | メディベイション テクノロジーズ エルエルシー | 化合物及び使用方法 |
| US10822337B2 (en) | 2015-04-01 | 2020-11-03 | Rigel Pharmaceuticals, Inc. | TGF-β inhibitorC |
| JP6980534B2 (ja) | 2015-06-25 | 2021-12-15 | ザ チルドレンズ メディカル センター コーポレーション | 造血幹細胞の増大、富化、および維持に関する方法および組成物 |
| JP7080179B2 (ja) | 2016-03-15 | 2022-06-03 | ザ チルドレンズ メディカル センター コーポレーション | 造血幹細胞の増大に関する方法および組成物 |
| ES2787449T3 (es) * | 2016-06-13 | 2020-10-16 | Genfleet Therapeutics Shanghai Inc | Compuesto de alfa y beta-amida insaturada derivado de benzotriazol usado como inhibidor de TGF-betaRI |
| US11266647B2 (en) * | 2016-10-26 | 2022-03-08 | Icahn School Of Medicine At Mount Sinai | Method for increasing cell proliferation in pancreatic beta cells, treatment method, and composition |
| TW201817726A (zh) | 2016-11-14 | 2018-05-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | ３，４－二吡啶基吡唑類衍生物、其製備方法及其在醫藥上的應用 |
| US11547712B2 (en) | 2017-11-20 | 2023-01-10 | Icahn School Of Medicine At Mount Sinai | Kinase inhibitor compounds and compositions and methods of use |
| WO2019114792A1 (fr) * | 2017-12-13 | 2019-06-20 | 劲方医药科技(上海)有限公司 | Forme cristalline et forme de sel d'un inhibiteur de tgf-βri et procédé de préparation correspondant |
| WO2019136320A1 (fr) | 2018-01-05 | 2019-07-11 | Icahn School Of Medicine At Mount Sinai | Procédé d'augmentation de la prolifération de cellules bêta pancréatiques, procédé de traitement et composition |
| CN112135613A (zh) | 2018-03-20 | 2020-12-25 | 西奈山伊坎医学院 | 激酶抑制剂化合物和组合物及使用方法 |
| TW202012390A (zh) * | 2018-06-29 | 2020-04-01 | 日商日本歐愛特農業科技股份有限公司 | 新穎之經取代吡唑衍生物 |
| EP3886854A4 (fr) | 2018-11-30 | 2022-07-06 | Nuvation Bio Inc. | Composés pyrrole et pyrazole et leurs procédés d'utilisation |
| JP2022511112A (ja) | 2018-12-11 | 2022-01-28 | セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー | Ａｌｋ５阻害剤としてのナフチリジンおよびキノリン誘導体 |
| CN110467601B (zh) * | 2019-08-29 | 2021-07-02 | 杭州市西溪医院 | 一种吡唑联吡啶酮类化合物、中间体及其制备方法及应用 |
| CA3160307A1 (fr) | 2019-11-22 | 2021-05-27 | Theravance Biopharma R&D Ip, Llc | 1,5-naphtyridines ou quinoleines substituees en tant qu'inhibiteurs d'alk5 |
| CA3160963A1 (fr) | 2019-11-28 | 2021-06-03 | Origo Biopharma, S.L. | Derives de benzylamide utilises en tant qu'inhibiteurs du recepteur i/alk5 du facteur de croissance transformant beta |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE640616A (fr) | 1962-12-19 | |||
| US3492397A (en) | 1967-04-07 | 1970-01-27 | Warner Lambert Pharmaceutical | Sustained release dosage in the pellet form and process thereof |
| US4060598A (en) | 1967-06-28 | 1977-11-29 | Boehringer Mannheim G.M.B.H. | Tablets coated with aqueous resin dispersions |
| US3538214A (en) | 1969-04-22 | 1970-11-03 | Merck & Co Inc | Controlled release medicinal tablets |
| US4173626A (en) | 1978-12-11 | 1979-11-06 | Merck & Co., Inc. | Sustained release indomethacin |
| US4925857A (en) * | 1989-03-22 | 1990-05-15 | Sterling Drug Inc. | Pyridinyl-1H-pyrazole-1-alkanamides as antiarrhythmic agents |
| JP3734180B2 (ja) * | 1994-12-28 | 2006-01-11 | エーザイ株式会社 | 新規ピラゾール誘導体 |
| US6514977B1 (en) | 1997-05-22 | 2003-02-04 | G.D. Searle & Company | Substituted pyrazoles as p38 kinase inhibitors |
| JP2002502380A (ja) | 1997-05-22 | 2002-01-22 | ジー．ディー．サール アンド カンパニー | ｐ３８キナーゼ阻害剤としてのピラゾール誘導体 |
| JP2002502379A (ja) | 1997-05-22 | 2002-01-22 | ジー．ディー．サール アンド カンパニー | ｐ３８キナーゼインヒビターとしての３（５）−ヘテロアリール置換ピラゾール |
| US6465493B1 (en) | 1999-04-09 | 2002-10-15 | Smithkline Beecham Corporation | Triarylimidazoles |
| CO5271680A1 (es) | 2000-02-21 | 2003-04-30 | Smithkline Beecham Corp | Compuestos |
| GB0007405D0 (en) | 2000-03-27 | 2000-05-17 | Smithkline Beecham Corp | Compounds |
| PE20020506A1 (es) | 2000-08-22 | 2002-07-09 | Glaxo Group Ltd | Derivados de pirazol fusionados como inhibidores de la proteina cinasa |
| GB0027987D0 (en) | 2000-11-16 | 2001-01-03 | Smithkline Beecham Plc | Compounds |
| US20040039198A1 (en) | 2000-11-16 | 2004-02-26 | Bender Paul E. | Compounds |
| GB0100762D0 (en) | 2001-01-11 | 2001-02-21 | Smithkline Beecham Plc | Novel use |
| JP2004521901A (ja) * | 2001-02-02 | 2004-07-22 | グラクソ グループ リミテッド | Ｔｇｆ阻害剤としてのピラゾール |
| ES2237671T3 (es) * | 2001-02-02 | 2005-08-01 | Smithkline Beecham Corporation | Derivados de pirazol contra la sobreexpresion de tgf. |
| GB0102672D0 (en) * | 2001-02-02 | 2001-03-21 | Glaxo Group Ltd | Compounds |
| WO2002072576A1 (fr) | 2001-03-09 | 2002-09-19 | Pfizer Products Inc. | Composes de benzimidazole anti-inflammatoires |
| EP1382603B1 (fr) | 2001-04-26 | 2008-07-23 | Eisai R&D Management Co., Ltd. | Compose azote a anneaux condenses possedant un groupe pyrazolyle et servant de substituant, et composition medicale le comprenant |
| AR039241A1 (es) | 2002-04-04 | 2005-02-16 | Biogen Inc | Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos |
| US20050245520A1 (en) | 2002-07-31 | 2005-11-03 | Nerina Dodic | 2-Phenylpyridin-4-yl derivatives as alk5 inhibitors |
| HRP20050250A2 (en) | 2002-09-18 | 2005-10-31 | Pfizer Products Inc. | Novel triazole and oxazole compounds as transforming growth factor (tfg) inhibitor |
| AU2003260810A1 (en) | 2002-09-18 | 2004-04-08 | Pfizer Products Inc. | Triazole derivatives as transforming growth factor (tgf) inhibitors |
| EA200500286A1 (ru) | 2002-09-18 | 2005-08-25 | Пфайзер Продактс Инк. | Новые изотиазольные и изоксазольные соединения в качестве ингибиторов трансформирующего фактора роста (тфр) |
| KR20050044807A (ko) * | 2002-09-18 | 2005-05-12 | 화이자 프로덕츠 인코포레이티드 | 전환 성장 인자 억제제로서의 피라졸 유도체 |
| DE60328028D1 (de) | 2002-09-18 | 2009-07-30 | Pfizer Prod Inc | Imidazolverbindungen als inhibitoren des transformierenden wachstumsfaktors (twf) |
| PA8595001A1 (es) * | 2003-03-04 | 2004-09-28 | Pfizer Prod Inc | Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf) |
-
2003
- 2003-09-08 KR KR1020057004598A patent/KR20050044807A/ko not_active Ceased
- 2003-09-08 HR HR20050247A patent/HRP20050247A2/hr not_active Application Discontinuation
- 2003-09-08 MX MXPA05002376A patent/MXPA05002376A/es active IP Right Grant
- 2003-09-08 BR BR0314302-3A patent/BR0314302A/pt not_active IP Right Cessation
- 2003-09-08 WO PCT/IB2003/003933 patent/WO2004026306A2/fr not_active Ceased
- 2003-09-08 AU AU2003259475A patent/AU2003259475A1/en not_active Abandoned
- 2003-09-08 EP EP03797443A patent/EP1542684B1/fr not_active Expired - Lifetime
- 2003-09-08 AP AP2005003263A patent/AP2005003263A0/xx unknown
- 2003-09-08 PL PL03375979A patent/PL375979A1/xx not_active Application Discontinuation
- 2003-09-08 EP EP09177298A patent/EP2165708A3/fr not_active Withdrawn
- 2003-09-08 JP JP2004568904A patent/JP4519657B2/ja not_active Expired - Fee Related
- 2003-09-08 AT AT03797443T patent/ATE450258T1/de not_active IP Right Cessation
- 2003-09-08 CA CA2496295A patent/CA2496295C/fr not_active Expired - Fee Related
- 2003-09-08 ES ES03797443T patent/ES2335099T3/es not_active Expired - Lifetime
- 2003-09-08 OA OA1200500078A patent/OA12929A/en unknown
- 2003-09-08 CN CNA038222655A patent/CN1681501A/zh active Pending
- 2003-09-08 DE DE60330362T patent/DE60330362D1/de not_active Expired - Lifetime
- 2003-09-08 EA EA200500377A patent/EA200500377A1/ru unknown
- 2003-09-15 PE PE2003000940A patent/PE20040988A1/es not_active Application Discontinuation
- 2003-09-16 AR ARP030103356A patent/AR041272A1/es unknown
- 2003-09-16 UY UY27985A patent/UY27985A1/es not_active Application Discontinuation
- 2003-09-17 US US10/667,189 patent/US6958354B2/en not_active Expired - Fee Related
- 2003-09-17 PA PA20038583201A patent/PA8583201A1/es unknown
-
2005
- 2005-02-16 NO NO20050838A patent/NO20050838L/no unknown
- 2005-02-17 IS IS7698A patent/IS7698A/is unknown
- 2005-03-16 EC EC2005005679A patent/ECSP055679A/es unknown
- 2005-03-16 CO CO05024529A patent/CO5550456A2/es not_active Application Discontinuation
- 2005-03-18 MA MA28154A patent/MA27440A1/fr unknown
- 2005-09-23 US US11/234,564 patent/US7151110B2/en not_active Expired - Fee Related
-
2006
- 2006-11-08 US US11/557,638 patent/US7638537B2/en not_active Expired - Fee Related
-
2009
- 2009-11-12 US US12/617,027 patent/US20100056571A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA27440A1 (fr) | Derives de pyrazole servant d'inhibiteurs du facteur de croissance transformant(tgf) | |
| MA27442A1 (fr) | Derives de triazole servant d'inhibiteurs du facteur de croissance transformant (tgf) | |
| MA27441A1 (fr) | Composes d'imidazole nouveaux servant d'inhibiteurs du facteur de croissance transformant (tgf) | |
| MA27443A1 (fr) | Oxazoles et thiazoles nouveaux servant d'inhibiteurs du facteur de croissance transformant (tgf) | |
| MA27444A1 (fr) | Derives d'isothiazole et d'isoxazole nouveaux servant d'inhibiteurs du facteur de croissance transformant (tgf) | |
| MXPA05009245A (es) | Nuevos compuestos de pirazina como inhibidores del factor de crecimiento transformante (tgf). | |
| NZ542622A (en) | Solid pharmaceutical compositions comprising a S1P receptor agonist and a sugar alcohol | |
| MXPA05008148A (es) | Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transformante (tgf). | |
| MA27093A1 (fr) | Derives de sulfonamides, leur preparation et leur application comme medicaments. | |
| MA26861A1 (fr) | Inhibiteurs non peptidiques de la liaison cellulaire sous la dependance de vla-4 utiles dans le traitement des maladies inflammatoires, auto-immunes et respiratoires | |
| MA26991A1 (fr) | Triazolopyridines servant d'agents anti-inflammatoires | |
| MA26946A1 (fr) | Derives de pyrazole nouveaux et leur utilisation comme inhibiteurs de proteine-kinases. | |
| MA27144A1 (fr) | Benzamide et heteroarylamide servant d'antagonistes du recepteur p2x7 | |
| MA27452A1 (fr) | Derives d'indole servant d'agonistes beta-2 | |
| MA27156A1 (fr) | NUCLEOSIDES 3- β-D-RIBOFURANOSYLTHIAZOLO[4,5-d] PYRIDIMINE ET LES UTILISATIONS DE CELLES-CI | |
| PL356252A1 (en) | Synergistic combination of pde inhibitors and beta 2 adrenoceptor agonist | |
| TN2010000230A1 (fr) | Agonistes nouveaux des recepteurs de glucocorticoides | |
| MA30514B1 (fr) | Nouveaux composes. | |
| MA29170B1 (fr) | Derives puriniques agissant comme des agonistes du recepteur a2a | |
| MA27448A1 (fr) | Derives de pyridine modulateurs du recepteur cb2 | |
| MA27867A1 (fr) | Nouveaux derives de 2h-pyridazine-3-one, compositions pharmaceutiques contenant ces derives et procede de preparation de l'ingredient actif. | |
| MA27692A1 (fr) | Composes derives de benzoxazinone, leur preparation et utilisation comme medicaments | |
| MA26690A1 (fr) | COMPOSITIONS PHARMACEUTIQUES CONTENANT DES DERIVES DE PYRIDO [1,2-a ] PYRAZINE ET PROCEDE POUR LEUR PREPARATION | |
| MA26701A1 (fr) | PYRAZOLOPYRIMIDINONES NOUVELLES INHIBITRICES DE PDE-5 GMPc, PROCEDE POUR LEUR PREPARATION ET COMPOSTIONS PHARMACEUTIQUES LES CONTENANT. | |
| MA27840A1 (fr) | Derives de (2-hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)-ethylamino)-propylphenyle servant d'agonistes beta2 |